Lmr Partners Llp Cut Its Pacific Biosciences Of Califor (PACB) Stake as Shares Declined

Pacific Biosciences of California, Inc. (NASDAQ:PACB) LogoInvestors sentiment decreased to 1.4 in 2019 Q2. Its down 0.45, from 1.85 in 2019Q1. It dived, as 18 investors sold PACB shares while 32 reduced holdings. 20 funds opened positions while 50 raised stakes. 86.37 million shares or 5.30% less from 91.20 million shares in 2019Q1 were reported. Deutsche National Bank & Trust Ag has 119,627 shares for 0% of their portfolio. Havens Advsr Lc holds 611,500 shares. Amer Interest Grp Inc holds 90,505 shares or 0% of its portfolio. Legal & General Group Public Ltd Com has invested 0% of its portfolio in Pacific Biosciences of California, Inc. (NASDAQ:PACB). The Connecticut-based Cubist Systematic Strategies Ltd Com has invested 0% in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Dekabank Deutsche Girozentrale holds 75,000 shares or 0% of its portfolio. France-based Natixis has invested 0.01% in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Ny State Common Retirement Fund stated it has 0% in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Barclays Public Limited holds 0% or 287,612 shares. 28,350 were accumulated by Lpl Financial Limited Liability Corporation. Northern stated it has 0% of its portfolio in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Lmr Partners Llp has invested 0.25% in Pacific Biosciences of California, Inc. (NASDAQ:PACB). 239,844 were accumulated by Wellington Mgmt Grp Llp. Capstone Invest Ltd Liability Company accumulated 0.02% or 452,230 shares. Wells Fargo Com Mn reported 0% of its portfolio in Pacific Biosciences of California, Inc. (NASDAQ:PACB).

Lmr Partners Llp decreased its stake in Pacific Biosciences Of Califor (PACB) by 42.09% based on its latest 2019Q2 regulatory filing with the SEC. Lmr Partners Llp sold 833,722 shares as the company’s stock declined 26.93% . The institutional investor held 1.15M shares of the capital goods company at the end of 2019Q2, valued at $6.94M, down from 1.98 million at the end of the previous reported quarter. Lmr Partners Llp who had been investing in Pacific Biosciences Of Califor for a number of months, seems to be less bullish one the $855.07M market cap company. The stock increased 1.45% or $0.08 during the last trading session, reaching $5.59. About 560,312 shares traded. Pacific Biosciences of California, Inc. (NASDAQ:PACB) has risen 52.97% since September 13, 2018 and is uptrending. It has outperformed by 52.97% the S&P500.

Lmr Partners Llp, which manages about $2.74 billion US Long portfolio, upped its stake in Anadarko Petroleum Corp (NYSE:APC) by 2.43 million shares to 2.45 million shares, valued at $172.91M in 2019Q2, according to the filing. It also increased its holding in Tata Motors Ltd (NYSE:TTM) by 635,534 shares in the quarter, for a total of 3.69M shares, and has risen its stake in Mitsubishi Ufj Financial Group (NYSE:MTU).

Analysts await Pacific Biosciences of California, Inc. (NASDAQ:PACB) to report earnings on November, 7. They expect $-0.14 earnings per share, up 26.32 % or $0.05 from last year’s $-0.19 per share. After $-0.16 actual earnings per share reported by Pacific Biosciences of California, Inc. for the previous quarter, Wall Street now forecasts -12.50 % EPS growth.

More notable recent Pacific Biosciences of California, Inc. (NASDAQ:PACB) news were published by: Globenewswire.com which released: “Pacific Biosciences Launches New Sequel II System, Featuring ~8 Times the DNA Sequencing Data Output – GlobeNewswire” on April 24, 2019, also Seekingalpha.com with their article: “Pacific Biosciences Stumbles As The U.K. Raises Concerns About Illumina’s Bid – Seeking Alpha” published on June 20, 2019, Nasdaq.com published: “The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health – Nasdaq” on June 21, 2019. More interesting news about Pacific Biosciences of California, Inc. (NASDAQ:PACB) were released by: Nasdaq.com and their article: “Merger or Not, Pacific Biosciences Needs to Deliver – Nasdaq” published on September 04, 2019 as well as Seekingalpha.com‘s news article titled: “PacBio Shares Reflect Some Ongoing Worries About The Illumina Deal – Seeking Alpha” with publication date: May 30, 2019.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Ratings Coverage

Among 2 analysts covering Pacific Biosciences (NASDAQ:PACB), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Pacific Biosciences has $8 highest and $8 lowest target. $8’s average target is 43.11% above currents $5.59 stock price. Pacific Biosciences had 3 analyst reports since April 2, 2019 according to SRatingsIntel. Stephens downgraded Pacific Biosciences of California, Inc. (NASDAQ:PACB) on Tuesday, April 2 to “Equal-Weight” rating. Cantor Fitzgerald maintained the shares of PACB in report on Thursday, June 20 with “Hold” rating.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.